Rick Pazdur has pointed out that the FDA is undergoing considerable changes, which could be linked to the increasing competition from China.
He suggests that while these challenges are significant, they also present opportunities for the agency to adapt and improve.
Pazdur emphasizes the need for the FDA to consider restructuring in response to these evolving realities.